Adsorption and Phase Transitions in Slit-like Pores with Differently Adsorbing Walls.
We study the adsorption of a lattice gas in a slit-like pore with different walls. The density profiles are evaluated in the framework of the mean-field approximation. We show that changes in the potential field exerted by one wall can lead to substantial modifications of the phase behavior of the fluids. Copyright 2001 Academic Press.
Capillary condensation of a model binary mixture in slit-like pores with differently adsorbing walls
Abstract We investigate capillary condensation of symmetric binary fluid mixtures confined in slit-like pores with differently adsorbing walls. The interactions between adsorbate particles are modeled by Lennard–Jones (12, 6) potentials and the adsorbing potentials are of the Lennard–Jones (9, 3) type. We concentrate on the evaluation of the phase diagrams for the mixture of different compositions placed in pores of different adsorption potentials. The calculations were performed by means of a density functional theory. Our investigations indicate that a binary mixture may exhibit rich phase behavior.
Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects
This study was designed to investigate the human absorption, disposition, and mass balance of 14C-brivaracetam, a novel high affinity SV2A ligand with potent anticonvulsant activity. Six healthy male subjects received a single p.o. dose of 14C-brivaracetam (150 mg, 82 μCi, or 3.03 MBq). Serial blood and complete urine and feces were collected until 144 h postdose. Expired air samples were obtained until 24 h. Brivaracetam was rapidly absorbed, with Cmax of 4 μg/ml occurring within 1.5 h of dosing. Unchanged brivaracetam amounted to 90% of the total plasma radioactivity, suggesting a modest first-pass effect. Plasma protein binding of radioactivity was low (17.5%). Urinary excretion exceeded 90% after 2 days, and the final mass balance reached 96.8% of the radioactivity in urine and 0.7% in feces. Only 8.6% of the radioactive dose was recovered in urine as unchanged brivaracetam, the remainder being identified as non–cytochrome P450 (P450)- and P450-dependent biotransformation products resulting from hydrolysis of the amide moiety (M9, 34.2%), hydroxylation of the n-propyl side chain (M1b, 15.9%), and a combination of these two pathways leading to the hydroxy acid (M4b, 15.2%). Minor amounts of taurine and glucuronic acid conjugates and other oxidized derivatives were also identified. Brivaracetam is completely absorbed, is weakly bound to plasma proteins, extensively biotransformed through several metabolic pathways, and eliminated renally.